New book by Larry Connors Click here Improve your trading - See how
Mr. Zook is President of MedImmune, Chief Executive Officer of AstraZeneca North America, and Executive Vice President of Global Marketing AstraZeneca. MedImmune was acquired by AstraZeneca in June 2007. As Chief Executive Officer of AstraZeneca North America, Mr. Zook oversees AstraZeneca's business in the region, including MedImmune, the AstraZeneca US Business and the AstraZeneca Canadian Business.
A seasoned executive with more than twenty five years of experience in the pharmaceutical industry, Mr. Zook has been CEO of AstraZeneca US since 2006. He has held various sales and marketing positions in the organization, most recently serving as senior vice president for commercial operations. In that role, Zook was responsible for the company's marketing and sales organizations throughout the US. Mr. Zook joined AstraZeneca USA in 1997 and began his career in 1983 at Berlex Laboratories, where he held both sales and marketing positions.
Mr. Zook earned an associate's degree in chemical engineering from Pennsylvania State University and a bachelor's degree in biology from Frostburg University. He is a member of the board for First State Innovation, the Pennsylvania Division of the American Cancer Society and a member of the Board of Trustees for the Healthcare Leadership Council.
"As the most recent appointment to the Rib-X board, we are looking forward to working with Tony during this exciting time in the company's growth," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "Tony brings years of sales and marketing experience to his new role and we believe his insight will be extremely helpful as our compounds continue to move toward commercialization."
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria, and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late-stage clinical trials.
For further information please contact:
Media:
Irma Gomez-Dib
FD Life Sciences
Tel: 212-850-5761
irma.gomez-dib@fd.com
Investors:
John Capodanno
FD Life Sciences
Tel: 212-850-5705
John.capodanno@fd.com
SOURCE Rib-X Pharmaceuticals, Inc.
http://www.rib-x.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.